Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesCardiologyBlue Cross Blue Shield MA antihyperlipidemics Prio…
    Ask Trek AI about this page
    DraftBlue Cross Blue Shield - MassachusettsPolicy 013

    Antihyperlipidemic agents prior authorization and quantity limits

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 013 alerts

    Get alerted when Policy 013 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs prior authorization, quantity limit, and formulary requirements for select antihyperlipidemic medications for BCBSMA commercial members; affects providers submitting pharmacy or medical benefit requests.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyAntihyperlipidemic agents prior authorization and quantity limits
    Policy CodePolicy 013
    Change TypeMaterial updates — Tryngolza addedPraluent/Repatha trial requirement revised
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization with recent LDL or triglyceride labs and documentation of prior therapies and adherence as specified.
    SourceLink
    POLICY UPDATE CHANGES

    Addition of Tryngolza to the policy.

    Updated removal of trial of three statins requirement for Praluent and Repatha.

    Updated to add Repatha indication previously (historic note).

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 monthsstandard length of approval
    Evkeeza, Juxtapid, Nexletol, Nexlizet, Leqvio, Repatha, Praluentagents with PA
    3 monthsinitial Leqvio approval
    130 daysprior use look-back
    within 12 monthslab recency for initiation
    within 3 monthslab recency for continuation

    Medication Coverage Criteria

    Evkeeza (evinacumab) — Medical necessity

    Covered when ALL of the following are met

    Evkeeza criteria: 1) A confirmed diagnosis of Homozygous Familial Hypercholesterolemia (HoFH); 2) Used as adjunct therapy to diet and maximally tolerated statin therapy in combination with ezetimibe; 3) Recent cholesterol labs with values within 12 months; 4) Current treatment with Praluent or Repatha unless clinically contraindicated to PCSK9 inhibitors.

    Juxtapid (lomitapide) — Medical necessity

    Covered when ALL of the following are met

    Juxtapid criteria: 1) A confirmed diagnosis of Homozygous Familial Hypercholesterolemia (HoFH); 2) Used as adjunct therapy to diet and maximally tolerated statin therapy in combination with ezetimibe; 3) Recent cholesterol labs with values OR use of LDL apheresis.

    Leqvio (inclisiran) — Initial and continuation criteria

    Initial request covered when ALL of the following are met

    Leqvio initial criteria: 1) A confirmed diagnosis of primary hyperlipidemia OR Heterozygous Familial Hypercholesterolemia (HeFH) OR established cardiovascular disease; 2) Age ≥18 years; 3) Evaluation in a lipid program staffed by a board-certified cardiologist or endocrinologist; 4) Recent LDL labs with values within 12 months; 5) Used as adjunct therapy to diet and maximally tolerated statin therapy in combination with ezetimibe OR previous treatment failure with 3 statin medications (at least 2 high potency) plus ezetimibe; 6) Previous treatment failure with Repatha.

    Initial approval duration: 3 months (encompassing one 6-month shot)

    Leqvio continuation criteria: 1) Adherence to current therapy verified with claims data; 2) Current (<3 months ago) submitted lab values show maintained improvement in LDL levels.<3 months

    Continued coverage duration: 12 months.

    Nexletol / Nexlizet (bempedoic acid ± ezetimibe) — Medical necessity

    Covered when ALL of the following are met

    Nexletol/Nexlizet criteria: A confirmed diagnosis of one of the following: Heterozygous Familial Hypercholesterolemia (HeFH), OR established cardiovascular disease, OR at high risk for cardiovascular disease event but without established CVD; used as adjunct to diet and maximally tolerated statin therapy where specified.

    Praluent (alirocumab) — Initiation and continuation criteria

    Initiation requests covered when ALL of the following are met

    Praluent initiation criteria: 1) A confirmed diagnosis of HeFH OR HoFH OR established cardiovascular disease; 2) Evaluation in a lipid program staffed by a board-certified cardiologist or endocrinologist; 3) Recent LDL labs with values within 12 months; 4) Used as adjunct therapy to diet and maximally tolerated statin therapy in combination with ezetimibe; 5) Previous treatment failure with Repatha.

    Initial approval duration: 3 months.

    Praluent continuation criteria: 1) Adherence to current therapy verified with claims data; 2) Current (<3 months ago) submitted lab values show maintained improvement in LDL levels.<3 months

    Continued coverage duration: 12 months.

    Repatha (evolocumab) — Medical necessity

    Covered when ALL of the following are met

    Repatha criteria: See initiation and continuation sections for specific Repatha criteria (diagnosis, recent LDL labs, use as adjunct to diet and maximally tolerated statin therapy with ezetimibe, and other requirements).

    Criteria structure referenced in document excerpt.

    Repatha — Initiation (medically necessary criteria)

    Repatha may be covered when ALL of the following are met:

    Diagnosis: A confirmed diagnosis of HeFH OR HoFH OR established cardiovascular disease.
    Labs: Recent LDL labs with values within 12 months.<12 months
    Therapy: Used as adjunct therapy to diet and maximally tolerated statin therapy in combination with ezetimibe (where specified).
    Specialist evaluation: Evaluation in a lipid program staffed by a board-certified cardiologist or endocrinologist (when specified).

    Repatha — Continuation

    Covered when ALL of the following are met for continuation:

    Adherence to current therapy verified with claims data.
    Labs: Current (<3 months ago) submitted lab values show maintained improvement in LDL levels.<3 months

    Tryngolza — Initiation (medically necessary criteria)

    Tryngolza may be covered when ALL of the following are met:

    Diagnosis: A confirmed diagnosis of Familial chylomicronemia syndrome confirmed by genetic mutation analysis.
    Specialist evaluation: Evaluation in a lipid program staffed by a board-certified cardiologist or endocrinologist.
    Triglycerides: Fasting triglyceride levels of '288Omg/dL' within the last 12 months (as stated in policy text).within 12 months

    Policy text contains typographical formatting for value.

    Adjunct therapy: Used as adjunct therapy to a low-fat diet.

    Initial approval duration: 3 months.

    Tryngolza — Continuation

    Covered when ALL of the following are met for continuation:

    Adherence to current therapy verified with claims data.
    Labs: Current (<3 months ago) submitted lab values show maintained improvement in triglyceride levels.<3 months
    Adjunct therapy: Used as adjunct therapy to a low-fat diet.

    Continued coverage duration: 12 months.

    The policy excerpt lists several commonly used statins and other lipid-lowering agents as having no coverage requirements under this policy. Examples explicitly named include Atorvastatin, Colesevelam, Colestipol, Ezetimibe, and Ezetimibe‑Simvastatin.

    This excerpt does not provide an exhaustive list of all formulary products; when prior prescription claim data are not available to demonstrate prior use, or when required documentation of trials/failures of formulary alternatives is absent, coverage may be precluded. The plan relies on claims records to establish prior use within the previous 130 days, and providers must supply supporting documentation when claims data are insufficient.

    Continuation (renewal) requests must include evidence of adherence from claims data and recent laboratory results showing maintained improvement. Specifically, the policy requires current lab values submitted within 3 months demonstrating maintained LDL or triglyceride improvement as applicable; absence of adherence verification or up-to-date labs may lead to denial of the continuation request.

    Lab, Age, and Prior-Use Requirements

    Lab recency
    Initiation lab recencyRecent LDL/cholesterol lab values required within 12 months for initiation of therapy
    Continuation lab recency (agent-specific)Some agents require current lab values for continuation (see continuation rules) — typically within 3 months
    Provider submission requirementProviders must submit recent cholesterol/LDL lab values as part of prior authorization documentation
    Age
    Minimum age for Leqvio initiation≥ 18 years
    Age citation contextAge >18 years is specified in initiation criteria and applicable when specified in agent criteria

    Provider Requirements and Submissions

    Prior Authorization

    Leqvio prior authorization details

    Prior authorization is required for Leqvio (inclisiran). Initial approvals are limited (see criteria) and continuation requires documentation of adherence and recent labs. Requests that do not meet PA criteria or lack required documentation (including documented trials/failures of formulary alternatives when applicable) may be denied.

    • Leqvio (inclisiran) is covered with prior authorization; SPBO pharmacy benefit coverage only.
    • Initial approval requires meeting initiation criteria (confirmed diagnosis, age >18, evaluation in lipid program by cardiologist/endocrinologist, recent LDL within 12 months, adjunct to diet and maximally tolerated statin ± ezetimibe or documented statin/ezetimibe failures).
    • Initial approval duration: 3 months (covers one 6‑month shot as specified).
    • Continuation requires evidence of adherence via claims data and submission of current labs (<3 months) demonstrating maintained LDL improvement.
    • Continued coverage duration: 12 months.

    Policy Scope and Applicability

    This policy governs prior authorization, quantity limit, and formulary requirements for select antihyperlipidemic agents used to lower LDL cholesterol, including novel agents such as PCSK9 inhibitors, ANGPTL3 inhibitors, and bempedoic acid (with or without ezetimibe). It applies to Boston‑area commercial members enrolled with Blue Cross Blue Shield of Massachusetts and to providers submitting pharmacy or medical benefit prior authorization requests for these agents.

    Clinical Definitions

    HoFH / HeFH
    HoFH definitionHomozygous Familial Hypercholesterolemia (HoFH) — a genetic disorder causing markedly elevated LDL; specified diagnosis that may qualify members for certain therapies
    HeFH definitionHeterozygous Familial Hypercholesterolemia (HeFH) — a genetic disorder causing elevated LDL; specified diagnosis for therapy qualification
    Clinical relevanceHoFH and HeFH are listed diagnoses in initiation criteria for agents such as Evkeeza, Juxtapid, Nexletol/Nexlizet and PCSK9 inhibitors
    HeFH / HoFH / Familial chylomicronemia syndrome
    HeFHHeterozygous Familial Hypercholesterolemia (HeFH) — defined as HeFH in policy initiation criteria for multiple agents
    HoFHHomozygous Familial Hypercholesterolemia (HoFH) — defined as HoFH in policy initiation criteria for multiple agents
    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyAntihyperlipidemic agents prior authorization and quantity limits
    Policy CodePolicy 013
    Change TypeMaterial updates — Tryngolza addedPraluent/Repatha trial requirement revised
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization with recent LDL or triglyceride labs and documentation of prior therapies and adherence as specified.
    SourceLink
    On This Page
    Medication Coverage CriteriaLab, Age, and Prior-Use RequirementsProvider Requirements and SubmissionsPolicy Scope and ApplicabilityClinical Definitions
    Age >18 years (when specified).
    >18 years
    Provider verificationAge must be documented in the prior authorization request
    Fasting triglyceride
    Fasting triglyceride value from policyRecorded in policy text as '288Omg/dL' for fasting triglycerides within last 12 months
    ContextThis value appears in Tryngolza initiation criteria and is noted in the policy as captured text (possible typographical error)
    Required timingFasting triglyceride level must be within the last 12 months
    LDL lab recency for initiation
    LDL lab recency for initiationRecent LDL labs with values must be within 12 months for initiation
    Applies toSpecified in initiation criteria for PCSK9 agents and other antihyperlipidemic therapies
    DocumentationRecent LDL lab results must be submitted with the prior authorization request
    Lab recency for continuation
    Lab recency for continuationCurrent submitted lab values must be within 3 months for continuation requests
    Adherence requirementContinuation also requires adherence to current therapy verified with claims data
    Typical continuation durationWhen continuation criteria met, continued coverage duration is typically 12 months
    Prior use look-back period
    Prior use look-back periodThe plan uses prescription claim records to establish prior use within the previous 130 days
    Use for step therapyPrior use within 130 days is used to document trial and failure of formulary alternatives
    Provider documentation when claims not availableAdditional documentation required from provider when historic prescription claim data is not available
    Denial Risk

    Requests that do not meet prior authorization

    Requests that fail to meet the plan's prior authorization or step therapy requirements, or that lack required provider documentation, risk denial. The plan uses prescription claims to establish prior use/step therapy within the prior 130 days; when claims history is insufficient, the provider must supply supporting documentation.

    • Requests without documented failure or contraindication to at least two covered formulary alternatives (when applicable) may be denied.
    • If historical prescription claims do not establish prior use or step therapy, additional provider documentation is required.
    • Requests not meeting PA requirements or lacking documented failures/contraindications may be denied.
    Denial Risk

    Continuation lab/adherence requirements

    For continuation of therapy, submit evidence of adherence and recent labs. Absence of adherence verification or labs within the specified timeframe (<3 months) may result in denial of continued coverage.

    • Provide claims-based verification of adherence to current therapy.
    • Submit current laboratory results dated within the last 3 months demonstrating maintained improvement in LDL (or triglyceride levels where applicable).
    • Lack of adherence evidence or labs <3 months will risk denial for continuation requests.
    Documentation Required

    Provider documentation for trials, failures, and exceptions

    Document all trials, failures, and clinical reasons preventing use of formulary alternatives. Include drug names, strengths, dates, and specific rationale for failure or contraindication to support exceptions or approval when prescription claims are insufficient.

    • When alternatives were tried, provide name, strength, dates of use (if available), and details of treatment failure.
    • If a formulary alternative was not tried for clinical reasons, provide the specific clinical rationale preventing the trial or switch.
    • For exception/individual consideration requests, include supporting clinical documentation (notes, literature, guidelines, compendia references).
    Step Therapy

    Step therapy / alternatives required

    The plan requires step therapy or documented trial/failure of formulary alternatives when available. The plan may use prescription claims to confirm prior use; if claims do not demonstrate required trials, provide supporting documentation of trials/failures or clinical contraindications.

    • Step therapy: member must have prior treatment failure with, or contraindication to, at least two covered formulary alternatives for non‑covered medications when available.
    • Plan will check prescription claims to establish prior use/step therapy; absence of claim evidence requires provider-submitted documentation.
    • Document the name, strength, dates, and reason for failure for each alternative tried.
    Note

    Submission form

    Use the Massachusetts Standard Form for Medication Prior Authorization Requests (eForm) when submitting PA requests. If eForm submission is not used, print and fax the standard MA Medication Prior Authorization Request form #434 with all supporting documentation.

    • Electronic submission: Massachusetts Standard eForm (link on BCBSMA site).
    • Paper submission: Print and fax form #434 with supporting clinical documentation to Pharmacy Operations as instructed.
    Familial chylomicronemia syndromeRequires confirmation by genetic mutation analysis for Tryngolza initiation; fasting triglyceride criteria also apply
    Related notesThese genetic diagnoses are specified to determine eligibility for certain therapies and require supporting documentation as part of prior authorization